Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

Price is unknown


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments. It offers drugs for urological diseases, inflammation and allergies, hematologic malignancies, cardiovascular and metabolic diseases, gastrointestinal disorders, and other diseases. The company's products include Zalutia for urinary disorder caused by benign prostatic; Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Cialis for erectile dysfunction; Vidaza for myelodysplastic syndrome; Cylocide for solid tumor and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva for humanized anti-CD20 monoclonal antibody; Defiterio sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku Co., Ltd.'s products also comprise Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler solution for allergic rhinitis; Azunol Gargle liquid, a gargling solution containing azulene; Isobide for oral osmotic diuresis/meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for cancer and chronic pain. In addition, it researches, develops, and markets drugs in the areas of gynecology, otorhinolaryngology, and orthopedics. Further, the company provides functional foods, such as health food ingredients, preservatives, protein preparations, supplements, and spice and condiments. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19 Mar '20 Mar '21 Mar '22
Earnings BIT 17,080.00
20,645.00
21,669.00
26,135.00
32,005.00
growth rate 20.9% 5.0% 20.6% 22.5%
Avg.PE 22.05
22.05
growth rate 0.0%
ROA 3.55
4.22
4.96
4.74
4.78
8.21
8.38
9.97
9.81
11.13
growth rate 18.9% 17.5% -4.4% 0.8% 71.8% 2.1% 19.0% -1.6% 13.5%
ROE 4.48
5.35
6.31
6.06
6.23
10.85
10.81
12.52
12.03
13.45
growth rate 19.4% 17.9% -4.0% 2.8% 74.2% -0.4% 15.8% -3.9% 11.8%
ROIC 4.47
5.34
6.29
6.05
6.21
10.82
10.80
12.51
12.02
13.45
growth rate 19.5% 17.8% -3.8% 2.6% 74.2% -0.2% 15.8% -3.9% 11.9%
Cur. Ratio 4.75
4.52
4.89
4.53
4.15
3.66
4.36
4.35
4.88
4.41
growth rate -4.8% 8.2% -7.4% -8.4% -11.8% 19.1% -0.2% 12.2% -9.6%
Quick Ratio 3.72
3.48
3.65
3.24
3.07
2.81
3.23
3.47
3.53
3.18
growth rate -6.5% 4.9% -11.2% -5.3% -8.5% 15.0% 7.4% 1.7% -9.9%
Leverage 1.26
1.27
1.27
1.28
1.32
1.32
1.26
1.25
1.20
1.21
growth rate 0.8% 0.0% 0.8% 3.1% 0.0% -4.6% -0.8% -4.0% 0.8%
Balance Sheet Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19 Mar '20 Mar '21 Mar '22
Acct.Receivable 40,164.00
46,555.00
41,522.00
39,797.00
43,178.00
growth rate 15.9% -10.8% -4.2% 8.5%
Acct.Payable 8,639.00
7,986.00
11,213.00
9,543.00
21,022.00
growth rate -7.6% 40.4% -14.9% 120.3%
Cur.Assets 97,953.00
110,720.00
121,925.00
139,090.00
149,724.00
growth rate 13.0% 10.1% 14.1% 7.7%
Total Assets 158,192.00
168,763.00
175,017.00
197,028.00
219,943.00
growth rate 6.7% 3.7% 12.6% 11.6%
Cash 21,067.00
31,519.00
36,005.00
47,770.00
60,566.00
growth rate 49.6% 14.2% 32.7% 26.8%
Inventory 20,345.00
19,371.00
29,893.00
35,523.00
38,066.00
growth rate -4.8% 54.3% 18.8% 7.2%
Cur.Liabilities 22,454.00
25,406.00
24,965.00
31,514.00
32,029.00
growth rate 13.2% -1.7% 26.2% 1.6%
Liabilities 32,505.00
33,574.00
29,258.00
34,486.00
39,058.00
growth rate 3.3% -12.9% 17.9% 13.3%
Equity 125,450.00
134,936.00
145,490.00
162,254.00
180,585.00
growth rate 7.6% 7.8% 11.5% 11.3%
Common Shares 68.00
67.00
67.00
67.00
67.00
67.00
5,174.00
5,174.00
5,174.00
5,174.00
5,174.00
growth rate -1.5% 0.0% 0.0% 0.0% 0.0% 7,622.4% 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19 Mar '20 Mar '21 Mar '22
Capital Expenditures 4,017.00
1,351.00
1,817.00
2,168.00
3,137.00
growth rate -66.4% 34.5% 19.3% 44.7%
Cash Dividends 3,768.00
3,698.00
5,651.00
6,196.00
6,799.00
growth rate -1.9% 52.8% 9.6% 9.7%
Cash From OA 6,719.00
15,310.00
12,737.00
21,388.00
21,316.00
growth rate 127.9% -16.8% 67.9% -0.3%
FCF 2,542.00
2,388.00
4,752.00
4,848.00
7,211.00
14,564.00
2,542.00
13,852.00
10,920.00
19,220.00
18,179.00
growth rate -6.1% 99.0% 2.0% 48.7% 102.0% -82.6% 444.9% -21.2% 76.0% -5.4%
Income Statement Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19 Mar '20 Mar '21 Mar '22
Sales 101,448.00
114,716.00
116,637.00
121,885.00
137,484.00
growth rate 13.1% 1.7% 4.5% 12.8%
Op.Income 17,080.00
20,645.00
21,669.00
26,135.00
32,005.00
growth rate 20.9% 5.0% 20.6% 22.5%
IBT 17,450.00
21,539.00
22,441.00
28,758.00
33,301.00
growth rate 23.4% 4.2% 28.2% 15.8%
Net Income 12,953.00
16,302.00
16,866.00
20,702.00
24,986.00
growth rate 25.9% 3.5% 22.7% 20.7%
EPS 55.04
68.87
85.25
87.26
94.10
174.42
192.31
242.04
250.42
307.37
growth rate 25.1% 23.8% 2.4% 7.8% 85.4% 10.3% 25.9% 3.5% 22.7%
Gross Profit 54,519.00
63,764.00
63,482.00
71,931.00
87,293.00
growth rate 17.0% -0.4% 13.3% 21.4%
R&D 13,221.00
16,701.00
13,994.00
16,104.00
22,863.00
growth rate 26.3% -16.2% 15.1% 42.0%

Quarterly Statements

Item Name Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Earnings BIT 5,772.00
16,449.00
5,056.00
7,817.00
2,683.00
growth rate 185.0% -69.3% 54.6% -65.7%
Balance Sheet Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Acct.Receivable 39,797.00
41,771.00
39,493.00
48,878.00
43,178.00
growth rate 5.0% -5.5% 23.8% -11.7%
Acct.Payable 9,543.00
9,069.00
7,173.00
8,991.00
21,022.00
growth rate -5.0% -20.9% 25.4% 133.8%
Cur.Assets 139,090.00
143,004.00
146,788.00
148,535.00
149,724.00
growth rate 2.8% 2.7% 1.2% 0.8%
Total Assets 197,028.00
200,114.00
204,052.00
204,795.00
219,943.00
growth rate 1.6% 2.0% 0.4% 7.4%
Cash 47,770.00
49,415.00
54,300.00
44,330.00
60,566.00
growth rate 3.4% 9.9% -18.4% 36.6%
Inventory 35,523.00
35,499.00
35,552.00
37,628.00
38,066.00
growth rate -0.1% 0.2% 5.8% 1.2%
Cur.Liabilities 31,514.00
26,590.00
26,155.00
24,508.00
32,029.00
growth rate -15.6% -1.6% -6.3% 30.7%
Liabilities 34,486.00
29,650.00
29,163.00
27,556.00
39,058.00
growth rate -14.0% -1.6% -5.5% 41.7%
Equity 162,254.00
170,170.00
174,593.00
176,941.00
180,585.00
growth rate 4.9% 2.6% 1.3% 2.1%
Common Shares 5,174.00
5,174.00
5,174.00
5,174.00
5,174.00
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Income Statement Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Sales 30,048.00
41,157.00
30,411.00
34,650.00
31,266.00
growth rate 37.0% -26.1% 13.9% -9.8%
Op.Income 5,772.00
16,449.00
5,056.00
7,817.00
2,683.00
growth rate 185.0% -69.3% 54.6% -65.7%
IBT 7,673.00
16,596.00
5,654.00
8,312.00
2,739.00
growth rate 116.3% -65.9% 47.0% -67.1%
Net Income 5,617.00
12,341.00
4,220.00
6,045.00
2,380.00
growth rate 119.7% -65.8% 43.3% -60.6%
Gross Profit 18,240.00
27,926.00
19,053.00
21,388.00
18,926.00
growth rate 53.1% -31.8% 12.3% -11.5%
R&D 4,645.00
3,699.00
6,306.00
5,701.00
7,157.00
growth rate -20.4% 70.5% -9.6% 25.5%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

B (81.19)

YOY Growth Grade:

C (59.93)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 22.05 22.05
EPS / Growth 3.76

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 10.6%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 10.6% 10.6% 10.6%
Future PE 0.01 14.43 14.43
Future EPS 10.32 10.32 10.32
Value Price
MOS %
0.03
36.79
36.79
MOS Price 0.01 18.40 18.40
IRT

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.